Quote:

---

That means that 10% of all patients have significantly less CCR5 molecules. So if CCR5 blockade works in covid, it works significantly better in CCR5delta32 heterozygous mutants.

---

That 10% single allele is of those who have European heritage. The double allele in that population is 1%. I would guess in the American population single allele would be around 8%. Which would work out to 20 patients in the leronlimab arm. Too small of a population to draw any firm conclusions.